Discontinued — last reported Q1 '25
Other Income & Expense
Net Unrealized Loss on Equity Securities
Vertex Pharmaceuticals Net Unrealized Loss on Equity Securities increased by 300.0% to $38.5M in Q1 2025 compared to the prior quarter. Year-over-year, this metric grew by 300.0%, from $9.63M to $38.5M. This is a positive signal — lower values indicate better performance for this metric.
Analysis
StatementIncome Statement
SectionOther Income & Expense
CategoryProfitability
SignalLower is better
VolatilityVolatile
First reportedQ1 2024
Last reportedQ1 2025Aug 5, 2025
How to read this metric
Higher losses indicate poor performance of the company's investment holdings or broader market downturns.
Detailed definition
This metric reflects the decrease in the fair market value of equity investments held by the company that have not yet b...
Peer comparison
Common for companies with large treasury or venture investment portfolios.
Metric ID:
gild_net_unrealized_loss_on_equity_securitiesHistorical Data
5 periods
| Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | |
|---|---|---|---|---|---|
| Value | $9.63M | $9.63M | $9.63M | $9.63M | $38.5M |
| QoQ Change | — | +0.0% | +0.0% | +0.0% | +300.0% |
| YoY Change | — | — | — | — | +300.0% |
Range$9.63M – $38.5M
CAGR+300.0%
Avg YoY Growth+300.0%
Median YoY Growth+300.0%
Current Streak4+ quarters growth
Net Unrealized Loss on Equity Securities at Other Companies
Frequently Asked Questions
- What is Vertex Pharmaceuticals's net unrealized loss on equity securities?
- Vertex Pharmaceuticals (VRTX) reported net unrealized loss on equity securities of $38.5M in Q1 2025.
- How has Vertex Pharmaceuticals's net unrealized loss on equity securities changed year-over-year?
- Vertex Pharmaceuticals's net unrealized loss on equity securities increased by 300.0% year-over-year, from $9.63M to $38.5M.
- What does net unrealized loss on equity securities mean?
- Loss from the decrease in value of stock investments that have not been sold yet.